AstraZeneca, Almirall announce $2.1B deal

AstraZeneca (NYSE:AZN) has closed on a deal to purchase the rights to lung drugs developed by Almirall (OTC:LBTSF), expanding the drug-maker's respiratory medicine portfolio.

"Our agreement with Almirall brings strategic and long-term value to AstraZeneca's strong respiratory franchise, one of our key growth platforms," says CEO Pascal Soriot.

The acquisition is worth up to $2.1B, with an initial $875M to be paid up front, and up to $1.2B in development.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs